Press Release Archive

October 3, 2011 - Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our

September 30, 2011 - Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony

(BUSINESS WIRE)--The Prix Galien USA committee recognized excellence in scientific innovation that improves the state of human health last night during the fifth annual Prix Galien Awards Gala. The Pro Bono Humanum Award and the Prix Galien USA 2011 Awards for best biotechnology product and best pharmaceutical agent were presented at a ceremony held at the Museum of Natural History in New York City. The Prix Galien USA 2011 Award

September 29, 2011 - Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems. The primary analysis of this double-

September 28, 2011 - The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit medicines were estimated to exceed $75 billion last year – an increase of

September 22, 2011 - Even Famous Faces Have an Advil® Story to Share

(BUSINESS WIRE)--After a day on the tennis court with his doubles partner and wife, Joy, Regis Philbin takes Advil® to relieve the pain that comes from a long match. Just like millions of Americans who rely on Advil® to relieve their tough pain, Regis and Joy have real stories to tell about how Advil® helps them keep doing what they love. The Philbins are the first famous faces to join real Advil® users who share their Advil® stories.

September 21, 2011 - New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia

(BUSINESS WIRE)--Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September 21-24 in Washington, D.C. BZA/CE is being developed by Pfizer for the

September 19, 2011 - Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.

(BUSINESS WIRE)--NEW YORK

September 12, 2011 - Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any

September 12, 2011 - Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress

(BUSINESS WIRE)--Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer’s renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT® (sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 – 27, 2011

September 8, 2011 - Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China

(BUSINESS WIRE)--MADISON, N.J.

September 8, 2011 - Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of Centrum

(BUSINESS WIRE)--Pfizer Consumer Healthcare, makers of Centrum® multivitamins, announced today the launch of ProNutrients™, a line of supplements from the most trusted multivitamin brand helping to increase confidence in supplementing and make nutrition possible. ProNutrients is a new line of dietary supplements launched by the makers of Centrum multivitamins, and is formulated to naturally work with a multivitamin. The line

September 7, 2011 - Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that nine abstracts about tofacitinib (development code CP-690,550), an investigational, novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting, which is being held November 5-9 in Chicago. Detailed Results Being Presented for

September 7, 2011 - Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the Investor Presentations

September 5, 2011 - Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period

(BUSINESS WIRE)--NEW YORK

September 1, 2011 - Pfizer Extends Tender Offer To Acquire Icagen, Inc.

(BUSINESS WIRE)--NEW YORK

September 1, 2011 - Pfizer Signs Agreement With MIT For Future Cambridge Research Center

(BUSINESS WIRE)--Pfizer Inc. today announced it has entered into a 10-year lease agreement with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, Massachusetts. Located at 610 Main Street South in Kendall Square, the new site will be the future location of Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units. The

August 31, 2011 - Pfizer Extends Tender Offer to Acquire Icagen, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes

August 29, 2011 - FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from Pfizer

(BUSINESS WIRE)--Pfizer Inc. has received FDA approval of XALKORI® (crizotinib) capsules – the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates and, as XALKORI received accelerated approval from the FDA, Pfizer is

August 27, 2011 - ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial

(BUSINESS WIRE)--PRINCETON, N.J.

August 26, 2011 - U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates (ORR) and, as

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.